Decay-accelerating factor 1 deficiency exacerbates Trypanosoma cruzi-induced murine chronic myositis

Muscle and Nerve

Volumn 46, Issue 4, 2012, Pages 582-587

  Solana, María E ^a   Ferrer, María F ^b   Novoa, María Mercedes ^a   Song, Wen Chao ^c   Gómez, Ricardo M ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Activation memory markers; Chagas disease; Chronic myositis; DAF knock out; Pathogenesis

Indexed keywords

CD44V ANTIGEN; DECAY ACCELERATING FACTOR 1; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CHAGAS DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; HISTOPATHOLOGY; IDIOPATHIC DISEASE; MALE; MORBIDITY; MOUSE; MUSCLE TISSUE; MYOSITIS; NONHUMAN; PARASITE LOAD; PARASITEMIA; PATHOGENESIS; PRIORITY JOURNAL; SKELETAL MUSCLE; T LYMPHOCYTE ACTIVATION; TRYPOMASTIGOTE;

ANIMALS; ANTIGENS, CD55; CHAGAS DISEASE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOSITIS; T-LYMPHOCYTES; TRYPANOSOMA CRUZI;

EID: 84866319217     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23347     Document Type: Article

References (36)

1. Engel AG, Hohlfeld R, Banker BQ. Inflammatory myopathies. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York: McGraw-Hill Book Co; 1994. p 1335-1383.
2. Askanas V, Engel WK, Mirabella M. Idiopathic inflammatory myopathies: inclusion-body myositis, polymyositis, and dermatomyositis. Curr Opin Neurol 1994; 7: 448-456.
3. Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010; 10: 346-352.
4. Gan L, Miller FW. State of the art: what we know about infectious agents and myositis. Curr Opin Rheumatol 2011; 23: 585-594.
5. Schofield CJ, Dias JC. The Southern Cone Initiative against Chagas disease. Adv Parasitol 1999; 42: 1-27.
6. Cossermelli W, Friedman H, Pastor EH, Nobre MR, Manzione A, Camargo ME, et al. Polymyositis in Chagas's disease. Ann Rheum Dis 1978; 37: 277-280.
7. Buckner FS, Wilson AJ, Van Voorhis WC. Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. Infect Immun 1999; 67: 403-409.
8. Dutra WO, Gollob KJ. Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis 2008; 21: 287-292.
9. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, Brutus L, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis 2010; 10: 556-570.
10. Andersson J, Englund P, Sunnemark D, Dahlstedt A, Westerblad H, Nennesmo I, et al. CBA/J mice infected with Trypanosoma cruzi: an experimental model for inflammatory myopathies. Muscle Nerve 2003; 27: 442-448.
11. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989; 7: 35-58.
12. An F, Li Q, Tu Z, Bu H, Chan CC, Caspi RR, et al. Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2009; 50: 3778-3782.
13. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005; 201: 567-577.
14. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002; 110: 1269-1274.
15. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, et al. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 2002; 161: 1077-1086.
16. Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, et al. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol 2007; 170: 1258-1266.
17. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007; 179: 5793-5802.
18. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530.
19. Gomez RM, Solana ME, Levander OA. Host selenium deficiency increases the severity of chronic inflammatory myopathy in Trypanosoma cruzi-inoculated mice. J Parasitol 2002; 88: 541-547.
20. Gonzalez Cappa SM, Chiale P, del Prado GE, Katzin AM, de Martini GW, de Isola ED, et al. [Isolation of a strain of Trypanosoma cruzi from a patient with chronic Chagas cardiomyopathy and its biological characterization]. Medicina (B Aires) 1980; 40( Suppl 1): 63-68.
21. Solana ME, Alba Soto CD, Fernandez MC, Poncini CV, Postan M, Gonzalez Cappa SM. Reduction of parasite levels in blood improves pregnancy outcome during experimental Trypanosoma cruzi infection. Parasitology 2009; 136: 627-639.
22. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A 1999; 96: 628-633.
23. Allenbach Y, Solly S, Gregoire S, Dubourg O, Salomon B, Butler-Browne G, et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009; 174: 989-998.
24. Pretre G, Olivera N, Cedola M, Haase S, Alberdi L, Brihuega B, et al. Role of inducible nitric oxide synthase in the pathogenesis of experimental leptospirosis. Microb Pathog 2011; 51: 203-208.
25. Cummings KL, Tarleton RL. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol 2003; 129: 53-59.
26. Hoft DF, Lynch RG, Kirchhoff LV. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi. J Immunol 1993; 151: 7038-7047.
27. Alba Soto CD, Mirkin GA, Solana ME, Gonzalez Cappa SM. Trypanosoma cruzi infection modulates in vivo expression of major histocompatibility complex class II molecules on antigen-presenting cells and T-cell stimulatory activity of dendritic cells in a strain-dependent manner. Infection and Immunity 2003; 71: 1194-1199.
28. Andersson J, Orn A, Sunnemark D. Chronic murine Chagas' disease: the impact of host and parasite genotypes. Immunol Lett 2003; 86: 207-212.
29. Marinho CR, D'Imperio Lima MR, Grisotto MG, Alvarez JM. Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infect Immun 1999; 67: 308-318.
30. Brandariz S, Schijman A, Vigliano C, Arteman P, Viotti R, Beldjord C, et al. Detection of parasite DNA in Chagas' heart disease. Lancet 1995; 346: 1370-1371.
31. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 2008; 8: 510-518.
32. Fang C, Miwa T, Shen H, Song WC. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J Immunol 2007; 179: 3178-3186.
33. Albareda MC, Olivera GC, Laucella SA, Alvarez MG, Fernandez ER, Lococo B, et al. Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol 2009; 183: 4103-4108.
34. Albareda MC, Laucella SA, Alvarez MG, Armenti AH, Bertochi G, Tarleton RL, et al. Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol 2006; 18: 465-471.
35. Cauvi DM, Cauvi G, Pollard KM. Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease. Arthritis Rheum 2007; 56: 1934-1944.
36. Mirkin GA, Celentano AM, Malchiodi EL, Jones M, Gonzalez Cappa SM. Different Trypanosoma cruzi strains promote neuromyopathic damage mediated by distinct T lymphocyte subsets. Clin Exp Immunol 1997; 107: 328-334.